# US 2025/0210201 A1 · Methods for stratification of parkinson's disease patients, systems and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0210201 A1
- Document ID: US20250210201A1
- Status: Published application
- Kind: A1
- Application number: 18/846,747
- Filed: 2023-03-15
- Published: 2025-06-26
- Earliest claimed: 2022-03-15
- Assignees: Universite Du Luxembourg
- Applicants: Université du Luxembourg
- Inventors: Giuseppe ARENA; Patrick MAY; Rejko KRÜGER; Anne GRÜNEWALD; Zied LANDOULSI
- Web page: https://patentgrep.com/patent/US20250210201A1

## CPC

- G16H 50/30: for calculating health indices; for individual health risk assessment
- C12Q 1/6883: for diseases caused by alterations of genetic material
- G01N 33/502: {for testing non-proliferative effects}
- G01N 33/5073: {Stem cells}
- G16B 20/20: Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
- G16H 20/10: relating to drugs or medications, e.g. for ensuring correct administration to patients
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY

## Abstract

The present invention provides for methods for the stratification of Parkinson's disease patients, systems and uses thereof. Provided are methods of diagnosis, uses and methods for screening, compositions and systems.

## Claims

### Claim 1

A method for stratifying whether or not a subject may be at a risk of suffering from Parkinson's disease (PD), comprising determining in a sample obtained from said subject its OXPHOS-mito polygenic risk score, wherein a high OXPHOS-mito polygenic risk score is indicative that said subject may be at a risk of developing PD.

### Claim 2

A method for stratifying whether or not a subject may be at a risk of suffering from Parkinson's disease (PD), comprising determining in a sample obtained from said subject its OXPHOS-mito polygenic risk score, wherein a low OXPHOS-mito polygenic risk score is indicative that said subject may not be at a risk of developing PD.

### Claim 3

A method for stratifying whether or not a subject suffering from Parkinson's disease (PD) may be at a risk of having mitochondrial dysfunction, comprising determining in a sample obtained from said subject its OXPHOS-mito polygenic risk score (PRS), wherein a high OXPHOS-mito PRS is indicative that said subject may be at a risk of developing mitochondrial dysfunction and/or wherein a low OXPHOS-mito PRS is indicative that said subject may not be at a risk of developing mitochondrial dysfunction.

### Claim 4 (depends on 3)

The method according to claim 3, wherein the mitochondrial dysfunction is characterized by increased mitochondrial oxygen consumption or decreased mitochondrial oxygen consumption.

### Claim 5

A method for stratifying whether or not a subject may be at risk suffering from Parkinson's disease (PD) with an early age of onset, comprising determining in a sample obtained from said subject its OXPHOS-mito polygenic risk score (PRS), wherein a high OXPHOS-mito PRS is indicative that said subject may be at a risk of developing Parkinson's disease (PD) with an early age of onset and/or wherein a low OXPHOS-mito PRS is indicative that said subject may not be at a risk of developing Parkinson's disease (PD) with an early age of onset.

### Claim 6

A compound for use in a method for preventing and/or treating Parkinson's disease in a subject, wherein said subject has a high OXPHOS-mito polygenic risk score.

### Claim 7 (depends on 6)

The compound for the use of claim 6, wherein said compound modulates mitochondrial oxygen consumption.

### Claim 8 (depends on 6, 7)

The compound for the use of claim 6 or 7, wherein modulation of mitochondrial oxygen consumption is an increase of mitochondrial oxygen consumption or a decrease of mitochondrial oxygen consumption.

### Claim 9 (depends on 6, 7, 8)

The compound for the use of any one of claims 6-8, wherein the compound is a drug that targets one or more electron transport chain proteins, wherein the one or more electron transport chain proteins are preferably selected from the group consisting of complexes I, II, III, and IV, and ATP synthase.

### Claim 10 (depends on 6, 7, 8, 9)

The compound for the use of any one of claims 6-9, wherein the compound is selected from the group consisting of Nobiletin, NAHS, Compound A and rT1.

### Claim 11 (depends on 6, 7, 8, 9, 10)

The compound for the use of any one of claims 6-10, wherein the compound is coenzyme Q10.

### Claim 12

Use of a cell being characterized by a high OXPHOS-mito polygenic risk score for screening compounds for the prevention or treatment of Parkinson's disease.

### Claim 13 (depends on 6)

The use of claim 6, wherein said compound modulates mitochondrial oxygen consumption.

### Claim 14 (depends on 6, 7)

The use of claim 6 or 7, wherein modulation of mitochondrial oxygen consumption is an increase of mitochondrial oxygen consumption or a decrease of mitochondrial oxygen consumption.

### Claim 15 (depends on 6, 7, 8)

The use of any one of claims 6 to 8, wherein said cell is a fibroblast, an induced pluripotent stem cell (iPSC) or induced pluripotent stem cell (iPSC)-derived neuronal progenitor cell (smNPC).

### Claim 16

A method for screening compounds for the prevention or treatment of Parkinson's disease, comprising bringing a cell being characterized by a high OXPHOS-mito polygenic risk score into contact with said compound and determining whether said compound modulates mitochondrial oxygen consumption of said cell.

### Claim 17 (depends on 16)

The method of claim 16, wherein modulation of mitochondrial oxygen consumption is an increase of mitochondrial oxygen consumption or a decrease of mitochondrial oxygen consumption.

### Claim 18 (depends on 16, 17)

The method of claim 16 or 17, wherein said cell is a fibroblast, an induced pluripotent stem cell (iPSC) or induced pluripotent stem cell (iPSC)-derived neuronal progenitor cell (smNPC).

### Claim 19

A composition comprising a cell being characterized by a high OXPHOS-mito polygenic risk score, optionally further comprising a buffer.

### Claim 20 (depends on 19)

The composition of claim 19, wherein said cell is a fibroblast, an induced pluripotent stem cell (iPSC) or induced pluripotent stem cell (iPSC)-derived neuronal progenitor cell (smNPC).

### Claim 21 (depends on 19, 20)

The composition of claim 19 or 20, further comprising a compound that modulates mitochondrial oxygen consumption of said cell.

### Claim 22

A system comprising a cell being characterized by a high OXPHOS-mito polygenic risk score, optionally further comprising a buffer.

### Claim 23 (depends on 22)

The system of claim 22, wherein said system is adapted for screening compounds which decreases/increases mitochondrial oxygen consumption of said cell.

### Claim 24 (depends on 22, 23)

The system of claim 22 or 23, wherein said cell is a fibroblast, an induced pluripotent stem cell (iPSC) or induced pluripotent stem cell (iPSC)-derived neuronal progenitor cell.

### Claim 25 (depends on 22, 23, 24)

The system of any one of claims 22-24, further comprising a compound that modulates mitochondrial oxygen consumption of said cell, wherein the iPSC-derived neuronal progenitor cell is preferably a neuronal progenitor cell (smNPC).

### Claim 26 (depends on 16, 17, 18)

A compound obtained or obtainable by the method of any one of claims 16 to 18.

### Claim 27 (depends on 6, 7, 8, 9, 10, 11, 26)

A method for stratifying whether or not a subject suffering from PD may be eligible for a treatment with a compound according to any one of claims 6-11 and 26, comprising determining in a sample obtained from said subject its OXPHOS-mito polygenic risk score (PRS), wherein a high OXPHOS-mito PRS is indicative that said subject may be eligible for treatment with said compound and/or wherein a low OXPHOS-mito PRS is indicative that said subject may not be eligible for treatment with said compound.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

The method of any one of claims 1-5 and 27, the compound for the use of any one of claims 6-11, the use of any one of claims 12-15, the method of any one of claims 16-18, the composition of any one of claims 19-21, the system of any one of claims 22-25, and/or the compound of claim 26, wherein Parkinson's disease is idiopathic Parkinson's disease.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The method of any one of claims 1-5 and 27-28, the compound for the use of any one of claims 6-11 and 28, the use of any one of claims 12-15 and 28, the method of any one of claims 16-18 and 28, the composition of any one of claims 19-21 and 28, the system of any one of claims 22-25 and 28, and/or the compound of any one of claims 26 and 28, wherein Parkinson's disease is Parkinson's disease is associated with mitochondrial dysfunction and/or aberrant mitochondrial oxygen consumption.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The method of any one of claims 1-5 and 27-29, the compound for the use of any one of claims 6-11 and 28-29, the use of any one of claims 12-15 and 28-29, the method of any one of claims 16-18 and 28-29, the composition of any one of claims 19-21 and 28-29, the system of any one of claims 22-25 and 28-29, and/or the compound of any one of claims 26 and 28-29, wherein the OXPHOS-mito polygenic risk score is obtained for a gene set comprising at least about 50, at least about 60, at least about 70, at least about 80, at least about 90, at least about 100, at least about 110, at least about 115, at least about 120, such as at least about 121, at least about 122, at least about 123, or about 124 of the OXPHOS-mito genes listed in Table 9.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

The method of any one of claims 1-5 and 27-30, the compound for the use of any one of claims 6-11 and 28-30, the use of any one of claims 12-15 and 28-30, the method of any one of claims 16-18 and 28-30, the composition of any one of claims 19-21 and 28-30, the system of any one of claims 22-25 and 28-30, and/or the compound of any one of claims 26 and 28-30, wherein the OXPHOS-mito polygenic risk score is obtained based on the OXPHOS-mito genes listed in Table 9.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The method of any one of claims 1-5 and 27-31, the compound for the use of any one of claims 6-11 and 28-31, the use of any one of claims 12-15 and 28-31, the method of any one of claims 16-18 and 28-31, the composition of any one of claims 19-21 and 28-31, the system of any one of claims 22-25 and 28-31, and/or the compound of any one of claims 26 and 28-31, wherein the OXPHOS-mito polygenic risk score is obtained for a gene set comprising at least about 50, at least about 60, at least about 70, at least about 80, at least about 90, at least about 100, at least about 110, at least about 115, at least about 120, such as at least about 121, at least about 122, at least about 123, or about 124 human genes having the Gene Ontology Database Pathways IDs of GO:0006119 (Oxidative phosphorylation), GO:0090324 (Negative regulation of oxidative phosphorylation), and GO:1903862 (Positive regulation of oxidative phosphorylation).

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

The method of any one of claims 1-5 and 27-32, the compound for the use of any one of claims 6-11 and 28-32, the use of any one of claims 12-15 and 28-32, the method of any one of claims 16-18 and 28-32, the composition of any one of claims 19-21 and 28-32, the system of any one of claims 22-25 and 28-32, and/or the compound of any one of claims 26 and 28-32, wherein the OXPHOS-mito polygenic risk score is obtained for a gene set comprising at least about 50, at least about 60, at least about 70, at least about 80, at least about 90, at least about 100, at least about 110, at least about 115, at least about 120, such as at least about 121, at least about 122, at least about 123, or about 124 genes selected from the group consisting of ABCD1, ACTN3, AFG1L, ATP5F1A, ATP5F1B, ATP5F1C, ATP5F1D, ATP5F1E, ATP5MC1, ATP5MC2, ATP5MC3, ATP5ME, ATP5MF, ATP5MG, ATP5PB, ATP5PD, ATP5PF, ATP5PO, ATP7A, BID, CCNB1, CDK1, CHCHD10, COA6, COQ9, COX10, COX15, COX411, COX412, COX5A, COX5B, COX6A1, COX6A2, COX6B1, COX6C, COX7A1, COX7A2, COX7A2L, COX7B, COX7C, COX8A, CYC1, CYCS, DLD, DMAC2L, DNAJC15, DNAJC30, FXN, MECP2, MLXIPL, MSH2, MYOG, NDUFA1, NDUFA10, NDUFA11, NDUFA12, NDUFA13, NDUFA2, NDUFA3, NDUFA4, NDUFA5, NDUFA6, NDUFA7, NDUFA8, NDUFA9, NDUFAB1, NDUFAF1, NDUFB1, NDUFB10, NDUFB11, NDUFB2, NDUFB3, NDUFB4, NDUFB5, NDUFB6, NDUFB7, NDUFB8, NDUFB9, NDUFC1, NDUFC2, NDUFC2-KCTD14, NDUFS1, NDUFS2, NDUFS3, NDUFS4, NDUFS5, NDUFS6, NDUFS7, NDUFS8, NDUFV1, NDUFV2, NDUFV3, NIPSNAP2, PARK7, PDE12, PGK1, PGK2, PINK1, PPIF, RHOA, SDHA, SDHAF2, SDHC, SDHD, SHMT2, SLC25A23, SLC25A33, SNCA, STOML2, SURF1, TAZ, TEFM, UQCC2, UQCC3, UQCR10, UQCR11, UQCRB, UQCRC1, UQCRC2, UQCRFS1, UQCRH, UQCRHL, UQCRQ, and VCP.

### Claim 34 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

The method of any one of claims 1-5 and 27-33, the compound for the use of any one of claims 6-11 and 28-33, the use of any one of claims 12-15 and 28-33, the method of any one of claims 16-18 and 28-33, the composition of any one of claims 19-21 and 28-33, the system of any one of claims 22-25 and 28-33, and/or the compound of any one of claims 26 and 28-33, wherein the OXPHOS-mito polygenic risk score is obtained using GWAS data for Parkinson's Disease.

### Claim 35 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)

The method of any one of claims 1-5 and 27-34, the compound for the use of any one of claims 6-11 and 28-34, the use of any one of claims 12-15 and 28-34, the method of any one of claims 16-18 and 28-34, the composition of any one of claims 19-21 and 28-34, the system of any one of claims 22-25 and 28-34, and/or the compound of any one of claims 26 and 28-34, wherein the OXPHOS-mito polygenic risk score is obtained using GWAS data as published by Nalls et al. Lancet Neurol. 2019 December; 18(12): 1091-1102 doi: 10.1016/S1474-4422(19)30320-5.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The method of any one of claims 1-5 and 27-35, the compound for the use of any one of claims 6-11 and 28-35, the use of any one of claims 12-15 and 28-35, the method of any one of claims 16-18 and 28-35, the composition of any one of claims 19-21 and 28-35, the system of any one of claims 22-25 and 28-35, and/or the compound of any one of claims 26 and 28-35, wherein the OXPHOS-mito polygenic risk score is obtained using GWAS data from the LuxPark dataset (Hipp et al., 2018 Front. Aging Neurosci. 10, 326. https://doi.org/10.3389/fnagi.2018.00326).

### Claim 37 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)

The method of any one of claims 1-5 and 27-36, the compound for the use of any one of claims 6-11 and 28-36, the use of any one of claims 12-15 and 28-36, the method of any one of claims 16-18 and 28-36, the composition of any one of claims 19-21 and 28-36, the system of any one of claims 22-25 and 28-36, and/or the compound of any one of claims 26 and 28-36, wherein the OXPHOS-mito polygenic risk score is obtained using GWAS data from the COURAGE-PD dataset (Grover et al., 2021, Mov Disord 36, 1689-1695. https://doi.org/10.1002/mds.28546).
